Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors

ConclusionCirculating Treg cells represent a promising potential dynamic biomarker to predict efficacy and differentiate atypical responses, including pseudoprogression and hyperprogression, after immunotherapy in patients with NSCLC.

Source: Cancer Immunology, Immunotherapy - July 18, 2021 Category: Cancer & Oncology Source Type: research